Francis Kynaston-Pearson: Breaking Down the Levels of Evidence in Clinical Research
Francis Kynaston-Pearson, Consultant Rheumatologist at Mediclinic Middle East, shared a post on LinkedIn:
”A new playlist starts today, the focus being research. Before discussing data that is helpful and relevant to patients, these initial videos cover the basics.
Doctors often tell patients their advice is evidenced based, backed by data and research. I wonder how meaningful this actually is to all my patients, especially those without a background or particular interest in the scientific process.
Todays video breaks down how doctors classify evidence into 5 tiers, from the opinion of experts (level 5) to the gold standard of randomised control trials (level 1 and even systematic reviews of said trials. You could even argue that international guidelines sit above this, combining multiple reviews with a consensus statement across a particular geography.
For anyone keen to understand the basics but too afraid to ask, this video is for you.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 9, 2026, 17:57CRISPR/Cas Gene Editing in β-Thalassemia: From Molecular Correction to Clinical Reality
-
Sep 9, 2026, 17:38Cardiovascular Health in Bleeding Disorders – EHC
-
Sep 9, 2026, 17:33Manasvi Shah: Co-Inheritance of Alpha Globin Gene Multiplication With Beta Globin Gene Abnormalities
-
Sep 9, 2026, 17:29Christina Crossette-Thambiah: One of the Largest Studies to Date in Antiphospholipid Syndrome
-
Sep 9, 2026, 17:25Alan Nurden: A miR-146a Variant Reveals a New Pathway Linking Platelet Metabolism and Thrombosis
-
Sep 9, 2026, 17:17When Is Thrombophilia Testing Appropriate and How Can the Evidence Guide Clinical Care? – ISTH
-
Sep 9, 2026, 16:07Zahra Safarzadeh: From Novel F8 Variant to Clinical Significance
-
Sep 9, 2026, 16:00Maximo Agustin Schiavone: HDL Beyond Cholesterol – Linking Lipids and Immunity
-
Sep 9, 2026, 15:56Abdul Mannan: When Antiseizure Drugs Alter DOAC Risk